Exhibit 10.63
(OSTEOTECH INC. LOGO)
Innovators in Musculoskeletal Science
▇▇▇ ▇▇▇▇▇-▇▇▇▇▇
President
Chief Operating Officer
November 29, 2005
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, Ph.D.
▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
Dear ▇▇▇:
This letter confirms the agreement between you and Osteotech, Inc., a
Delaware corporation (the "Company"), concerning the terms of your resignation
as an officer and employee of the Company and explains the separation
compensation benefits being offered to you. Should you decide to accept the
separation benefits described in this letter, you must sign and return the
General Release (the "Release"), attached as Exhibit A, within twenty-one (21)
days of the date of this letter. Upon your execution of the Release, the Company
will also sign the Company Release attached as Exhibit B to this letter. If you
do not execute the Release within such time period, you will not receive the
separation benefits described in this letter, and you will only be entitled to
receive the separation benefits set forth in the Employment Agreement dated
December 18, 1997 between you and the Company and your options will be
exercisable following the Termination Date (as defined below) in accordance with
the terms of relevant option agreement and option plan.
This letter outlines details regarding the date your employment with the
Company will end, your final pay, and other matters that apply to your
separation benefits. Your execution of the Release is your acceptance of the
separation benefits and other terms and conditions set forth in this letter.
1. TERMINATION DATE AND FINAL SALARY PAYMENT. Your employment relationship
with the Company will terminate effective November 30, 2005 (your "Termination
Date"). On your Termination Date you will receive all salary due to you
including pay through your Termination Date. You will receive payment for all
accrued and unused vacation credited to you as of your Termination Date on the
next regularly scheduled payroll date after the Termination Date. In addition,
following your submission of proper expense receipts or reports, you will
receive reimbursement for all expenses reasonably and necessarily incurred by
you in connection with the business of the Company prior to your Termination
Date.
2. HEALTH INSURANCE COVERAGE. Your current coverage under the Company's
standard medical, dental and life insurance programs will continue until
November 30, 2006. Payment for premiums for these programs shall continue during
that period in accordance with the Company's standard practice. You (and your
eligible dependents) will then have the right to
▇▇ ▇▇▇▇▇ ▇▇▇ - ▇▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ - (▇▇▇) ▇▇▇-▇▇▇▇
-1-
elect, at your own expense, continued coverage under the Company's health
insurance program as provided by the Consolidated Omnibus Budget Reconciliation
Act of 1985 ("COBRA"), provided you make a timely election for such continued
coverage. You will be provided with information and an opportunity to elect such
continuation coverage following the Termination Date, and if you make a timely
election for such continued coverage, it will be effective beginning December 1,
2006.
3. EMPLOYEE CONFIDENTIAL INFORMATION AND INVENTION AND NON-COMPETITION
AGREEMENT. You acknowledge and agree to continue to be bound by the Employee
Confidential Information and Invention and Non-Competition Agreement dated
November 15, 1995 (the "Nondisclosure and Non-Competition Agreement") which was
previously entered into between you and the Company in connection with your
employment with the Company and which remains in full force and effect following
the date hereof in accordance with its terms except as it may be amended by the
Consulting Agreement (as defined below) if you decide to execute the Consulting
Agreement.
4. SEPARATION BENEFITS. In consideration for your execution of the Release
and your other obligations to the Company, including, without limitation, your
obligations under the Nondisclosure and Non-Competition Agreement, the Company
agrees to provide the following separation benefits to you following the
Effective Date of the Release (as defined in the Release):
(a) SEVERANCE PAYMENT. The Company will pay you as severance twelve
(12) months of your regular base salary at the rate in effect as of the
Termination Date. This severance benefit will be paid in twenty-four (24) equal
bi-monthly installments on the Company's regularly scheduled payroll dates. The
first severance payment will be paid on the Company's first regularly scheduled
payroll date following the Effective Date of the Release. Each severance payment
will be reduced by applicable taxes.
(b) STOCK OPTIONS. All of your outstanding stock options granted under
the Company's 1991 Stock Option Plan and 2000 Stock Plan have previously vested.
In accordance with the Stock Option Detail Status Report as of October 31, 2005
attached as Exhibit C to this letter, you will have 302,243 vested option shares
as of the Termination Date. Effective as of the Effective Date of the Release,
the Company will extend the period of time in which you may exercise your stock
options, so that you will have two (2) years from the Termination Date (the
"Option Term") to exercise the options with respect to such vested shares,
provided that any options for which the original expiration date is prior to the
end of the Option Term shall expire on such original expiration date.
5. CONSULTING AGREEMENT. The Company agrees to retain you, and you agree to
serve the Company, as a consultant following your Termination Date under the
terms and conditions of the Consulting Agreement attached as Exhibit D to this
letter (the "Consulting Agreement"). The Consulting Agreement will be effective
as of the Effective Date of the Release.
6. CHANGE IN CONTROL AGREEMENT. Your Change in Control Agreement with the
Company, dated as of September 8, 2002 shall terminate as of the Termination
Date.
-2-
If you have any questions regarding the details in this letter or the
Release, please contact ▇▇▇▇▇▇▇ ▇▇▇▇▇ at (▇▇▇) ▇▇▇-▇▇▇▇. The Company wishes you
great success in your future endeavors.
OSTEOTECH, INC.
By: /s/ ▇▇▇ ▇▇▇▇▇-Akyaw
------------------------------------
▇▇▇ ▇▇▇▇▇-▇▇▇▇▇
Its: President and Chief Operating
Officer
-3-
EXHIBIT A--GENERAL RELEASE
In exchange for the benefits provided to me pursuant to the letter from
Osteotech Inc. ("Osteotech") to me dated November 29, 2005 (the "Termination
Letter"), the Consulting Agreement (the "Consulting Agreement") referred to in
the Termination Letter, the extension of the exercise period for my outstanding
Osteotech stock options provided to me in the Termination Letter and Osteotech's
execution of a release in favor of me, for myself, my heirs, administrators,
executors, representatives and/or assigns, I hereby voluntarily discharge and
release Osteotech and its affiliates, parent and subsidiary companies, officers,
directors, employees, agents, representatives, successors and assigns
(collectively the "Osteotech Releasees") from any and all claims or liabilities
of any kind or description, known or unknown, suspected or unsuspected, fixed or
contingent, which I ever had, now have or hereafter may have against each or any
of the Osteotech Releasees by reason of any matter whatsoever arising out of or
resulting from my employment at Osteotech and the termination of my employment
at Osteotech. This release of claims specifically includes, but is not limited
to, any claim of discrimination, including any claim arising under, or based
upon, the Age Discrimination in Employment Act (or the Older Workers Benefit
Protection Act), Title VII of the Civil Rights Act of 1964, as amended, the
Americans with Disabilities Act, the New Jersey Conscientious Employee
Protection Act and/or the New Jersey Law Against Discrimination, and any and all
contract, quasi-contract, estoppel, tort or statutory claims under federal,
state or local law arising out of or resulting from my employment at Osteotech
and the termination of my employment at Osteotech. Notwithstanding anything to
the contrary in this General Release, this General Release does not release the
Company from the performance of its obligations under the Termination Letter or
the Consulting Agreement.
I acknowledge and agree that I have been given at least twenty-one (21)
days to consider this General Release. I further acknowledge and agree that I
may cancel or revoke this General Release within seven (7) days after signing
it. To be effective, any notice of cancellation or revocation must be in writing
and delivered either by hand or mail within such seven (7) day period to Mr.
▇▇▇▇▇▇▇ ▇▇▇▇▇ at Osteotech. If delivered by mail, the notice of cancellation or
revocation must be (a) post-marked within the seven (7) day period; (b) properly
addressed to Mr. ▇▇▇▇▇▇▇ ▇▇▇▇▇, Osteotech, Inc., ▇▇ ▇▇▇▇▇ ▇▇▇, ▇▇▇▇▇▇▇▇▇, ▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇; and (c) sent by certified mail, return receipt requested. If I do
not deliver a letter revoking this General Release, then this General Release
shall become effective upon the expiration of the seventh (7th) day after I
executed this General Release (the "Effective Date"). I acknowledge and agree
that, if I exercise my right of cancellation or revocation, Osteotech shall be
relieved of all its obligations undertaken in the Consulting Agreement and
Termination Letter.
I acknowledge and agree that I fully understand this General Release, that
I was advised by Osteotech of my right to consult with independent counsel of my
choice before signing it, and that I am signing it voluntarily.
In addition, by executing this General Release, I acknowledge the terms of
my separation from the Company and agree to accept the terms of the Termination
Letter.
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, Ph.D.
Signature:
-----------------------------
Date:
----------------------------------
-4-
EXHIBIT B
COMPANY RELEASE
In exchange for the benefits provided to Osteotech, Inc. ("Osteotech") by
the Consulting Agreement (the "Consulting Agreement") referred to in the letter
from Osteotech to me dated November 29, 2005 (the "Termination Letter") dated as
of the date hereof between Osteotech and ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇ ("▇▇▇▇▇▇▇"),
Osteotech, for itself, its officers, directors, successors, agents,
representatives and assigns, hereby voluntarily discharges and releases ▇▇▇▇▇▇▇
and his heirs, administrators, executors, representatives and/or assigns
(collectively the "▇▇▇▇▇▇▇ Releasees"), from any and all claims or liabilities
of any kind or description, known or unknown, suspected or unsuspected, fixed or
contingent, which Osteotech ever had, now has or hereafter may have against each
or any of the ▇▇▇▇▇▇▇ Releasees by reason of any matter whatsoever arising out
of or resulting from ▇▇▇▇▇▇▇'▇ employment at Osteotech through the date hereof,
and his separation from such employment. Notwithstanding anything to the
contrary in this Company Release, this Company Release does not release ▇▇▇▇▇▇▇
from the performance of his obligations under the Termination Letter, the
Nondisclosure and Non-Competition Agreement (as defined in the Termination
Letter) or the Consulting Agreement. This Company Release shall become effective
upon the Effective Date of your General Release of even date hereof.
OSTEOTECH, INC.
By:
--------------------------------------
▇▇▇ ▇▇▇▇▇-▇▇▇▇▇
Its: President and Chief Operating Officer
Date:
-------------------
-5-
EXHIBIT C
STOCK OPTION DETAIL STATUS REPORT
AS OF OCTOBER 31, 2005
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇
AGREEMENT PLAN GRANT EXPIRATION
# ID DATE DATE TYPE PRICE $ GRANTED EXERCISED CANCELED OUTSTANDING
--------- ---- ---------- ---------- ---- ------- ------- --------- -------- -----------
1017 1991 12/15/1995 12/15/2005 NQ 4.6250 112,500 0 0 112,500
1067 1991 12/6/1996 12/6/2006 ISO 3.8330 22,500 0 0 22,500
1101 1991 7/31/1997 7/30/2007 NQ 8.5000 65,493 0 0 65,493
1165 1991 12/3/1998 12/3/2008 NQ 20.6670 22,500 0 0 22,500
1209 1991 12/9/1999 12/9/2009 ISO 15.8750 10,000 0 0 10,000
1242 2000 12/7/2000 12/7/2010 ISO 3.5000 10,000 0 0 10,000
1393 2000 8/2/2002 8/2/2012 NQ 8.9000 30,000 0 0 30,000
1468 2000 12/18/2003 12/18/2013 NQ 7.9600 15,000 0 0 15,000
1554 2000 12/16/2004 12/16/2014 NQ 5.3500 14,250 0 0 14,250
------- --- --- -------
TOTALS 302,243 0 0 302,243
======= === === =======
-6-
EXHIBIT D
CONSULTING AGREEMENT
This Agreement is entered into this 21st day of December, 2005 by and
between Osteotech Inc., a Delaware corporation having its principal place of
business at ▇▇ ▇▇▇▇▇ ▇▇▇, ▇▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇ (the "Company"), and ▇▇▇▇▇ ▇.
▇▇▇▇▇▇▇, Ph.D. ("Consultant").
RECITALS
A. Consultant has expertise in bone science, design and development of
allograft bone tissue products and other products for surgical procedures of the
spine and has substantial technical and business knowledge of the development,
manufacturing and marketing of such products.
B. The Company values the knowledge and expertise of Consultant and desires
to obtain consulting services from Consultant on the terms and conditions set
forth in this Agreement.
NOW, THEREFORE, the Company and Consultant agree as follows:
1. Retention of Consultant; Services to be Performed. The Company hereby
retains Consultant for the term of this Agreement to perform consulting services
as set forth in Schedule A (hereunder referred to as the "Services").
2. Compensation for Consulting Services. For Consultant's Services
hereunder, the Consultant shall be entitled to the following:
(a) For the first twelve (12) month period following the Effective
Date:
a. Compensation at the rate of $2,000 per day or $4,000 per 2
day Think Tank Session attended by Consultant. Currently six
(6) Think Tank Sessions are planned for 2006;
b. Compensation for all other requested Services to be paid at
the rate of one hundred sixty dollars ($160) per hour, not
to exceed $1,280 in any one day;
c. A minimum guarantee of $50,000, including the 6 Think Tanks
planned for 2006, to be paid to Consultant for the first
twelve (12) month period following the Effective Date (the
"First Period"), provided that such amount shall be paid to
Consultant notwithstanding the event that this Agreement is
terminated prior to the end of the First Period for any
reason other than by the Company under Section 6(b)(iii) or
by the Consultant under Section 6(c)(i), and in such event
such amount shall be paid within thirty (30) days after
Consultant's termination;
(b) For the second twelve (12) month period following the Effective
Date:
a. Compensation for requested Services to be paid at the rate
of one hundred sixty dollars ($160) per hour, not to exceed
$1,280 in any one day;
b. A minimum guarantee of $75,000 to be paid to Consultant for
the second twelve (12) month period following the Effective
Date (the "Second Period"), provided that such amount shall
be paid to Consultant notwithstanding the event that this
Agreement is terminated prior to the end of the Second
Period for any reason other than by the Company under
Section 6(b)(iii) or by the Consultant under Section
6(c)(i), and in such event such amount shall be paid within
thirty (30) days after Consultant's termination.
1
The Company shall pay consulting fees within 30 days after receipt of invoice.
3. Expenses. The Company shall reimburse Consultant for all reasonable
travel and other out-of-pocket expenses incurred by Consultant in rendering
Services hereunder, provided that the Company has approved such expenses in
advance. The Company shall pay such reimbursement within 30 days after receipt
of appropriate receipts or documentation of the expenses. Air travel expenses
will be reimbursed for coach class seating within the United States and for
business class seating Internationally. All travel must be booked through
Osteotech's travel representative.
4. Confidential Information and Invention and Non-Competition Agreement.
Consultant and the Company agree to continue to be bound by the Employee
Confidential Information and Invention and Non-Competition Agreement dated
November 15, 1995 (the "Nondisclosure and Non-Competition Agreement") which was
previously entered into between Consultant and the Company in connection with
Consultant's employment with the Company. The Nondisclosure and Non-Competition
Agreement will remain in full force and effect following the date hereof in
accordance with its terms; provided that the non-competition period in Section 1
of the Nondisclosure and Non-Competition Agreement will commence on the
Effective Date and end on the later of twenty-four (24) months after the
Effective Date and twelve (12) months after the termination of this Agreement
for any reason; and provided further that for purposes of Section 3 of the
Nondisclosure and Non-Competition Agreement, Consultant will be treated as being
"employed" by the Company until the termination of this Agreement.
5. Representations and Warranties. Consultant represents and warrants that
he will not make any misrepresentation or unauthorized statement about the
Company or its products or about the performance of Consultant's Services
hereunder, nor shall Consultant make any misrepresentation concerning any
Services rendered under this Agreement.
6. Term and Termination.
a. Term. The effective date of the Agreement (the "Effective Date")
shall be the effective date of the Release referred to in the letter from the
Company to Consultant dated November 29, 2005. The term of this Agreement shall
be a twenty-four (24) month period from the Effective Date of the Agreement, as
described in Section 2. Compensation for Consulting Services.
b. Termination by Company. Without prejudice to any other rights,
Company shall have the right to terminate this Agreement under the following
circumstances: (i) for any reason upon sixty (60) days written notice to
Consultant prior to the date of expiration of the then current term; (ii) at any
time in the event of death or serious disability of Consultant; and (iii) at any
time if Consultant fails to perform any material term of this Agreement and such
non-performance is not cured within thirty (30) days of written notice by
Company of such failure of performance.
c. Termination by Consultant. Consultant shall have the right to
terminate this Agreement under the following circumstances: (i) for any reason
upon sixty (60) days written notice to Company prior to the date of expiration
of the then current term; and (ii) at any time if Company fails to perform any
material term of this Agreement and such non-performance is not cured within
thirty (30) days written notice by Consultant of such failure of performance by
Company.
d. Rights and Obligations Upon Termination. If this Agreement is
terminated prior to the expiration of the then current term, Paragraphs 4, 5, 6
and 7 shall survive termination of this Agreement.
2
7. Disputes. All disputes arising with respect to this Agreement shall be
governed by the laws of New Jersey and adjudicated in a court of competent
jurisdiction in New Jersey, and Consultant hereby consents to personal
jurisdiction in the State of New Jersey.
8. Miscellaneous.
a. Assignment. Consultant may not assign any right nor delegate any
obligation under this Agreement without the prior written consent of the
Company. Any such attempted assignment or delegation without proper consent
shall be void.
b. Entire Understanding; Binding Agreement. This Agreement, as well as
the Nondisclosure and Non-Competition Agreement, constitute the final and
complete agreement between the Company and Consultant with respect to the
subject matter hereof, superseding any previous oral or written communication,
representation, understanding or agreement with the Company or any officer or
representative of the Company. This Agreement shall inure to the benefit of and
shall be binding upon the Company and its successors and assigns and upon
Consultant and his executors, administrator or representatives. No modification
of this Agreement shall be valid unless made in writing and signed by the
parties hereto and dated subsequent to the date hereof.
c. Notices. Any notice required or permitted to be given hereunder
shall be in writing and shall be deemed effective upon the personal delivery
thereof, if mailed, forty-eight (48) hours after having been deposited in the
United States mails, postage prepaid, and addressed to the party to whom it is
directed at the address set forth above (or such other address provided in
writing to the other party).
d. Injunctive Relief. Consultant acknowledges that it would be
difficult to fully compensate the Company for damages resulting from any breach
by Consultant of the provisions of Section 4 of this Agreement. Accordingly, in
the event of any actual or threatened breach of such provisions, the Company
shall (in addition to any other remedies that it may have) be entitled to
temporary and/or permanent injunctive relief to enforce such provisions, and
such relief may be granted without the necessity of proving actual damages.
e. Status of Consultant. Consultant is an independent contractor and
not an employee of the Company. Consultant has no authority to obligate the
Company by contract or otherwise. Consultant shall not be entitled to any
employee benefits that the Company provides to its employees. Consultant shall
be free to exercise discretion and independent judgment as to the method and
means of performance of the Services to be provided pursuant to this Agreement.
f. Severability. If any provision of the Agreement is for any reason
declared to be invalid or unenforceable, the validity and enforceability of the
remaining provisions shall not be affected thereby. Such invalid or
unenforceable provision shall be deemed modified to the extent necessary to
render it valid and enforceable, and if no modification shall render it valid
and enforceable, the Agreement shall be construed as if not containing such
provision and the rights and obligations of the parties shall be construed and
enforced accordingly.
g. No Waiver. No waiver by the parties, whether express or implied, of
any provision of this Agreement or of any breach or default shall constitute a
continuing waiver of such provision or a waiver of any other provision of this
Agreement.
h. Provisions. The provisions of this agreement shall inure to the
benefit of, and be binding upon each successor of the corporation, whether by
merger, consolidation, transfer of all or substantially all assets, or
otherwise.
3
IN WITNESS WHEREOF, the Company and Consultant have executed this Agreement
as of the date set forth in the first paragraph.
Osteotech, Inc.
Dated: By:
------------------ ------------------------------------
Name: ▇▇▇ ▇▇▇▇▇-▇▇▇▇▇
Title: President and Chief Operating
Officer
▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇, Ph.D.
Dated:
------------------ ----------------------------------------
Address: ▇▇ ▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
4
SCHEDULE A
SCOPE OF SERVICES:
The primary objective of the Consultant is to provide services and special
projects in all of the following areas;
1. Think Tanks
2. Clinical Activities
3. Research Activities
4. Educational activities for surgeons and customers in both
Domestic and International Markets.
The Consultant may attend professional meetings and participate as a
Faculty Member in Company training programs as part of the Consulting Services
provided.
5